Hardman & Co Research
Hardman & Co Research: Diurnal (DNL): Approaching a number of near-term
milestones
05-Nov-2019 / 07:30 GMT/BST
Hardman & Co Research: Approaching a number of near-term milestones
Diurnal (DNL) is a commercial-stage specialty pharmaceutical company focused
on diseases of the endocrine system. Its two lead products are targeting
rare conditions where medical need is currently unmet, with the aim of
building a long-term 'Adrenal Franchise'. The first product, Alkindi(R), is
being rolled out through key EU markets, and sales have exceeded the GBP1.0m
mark. Despite unexpected Phase III results, positive feedback from the EMA
has cleared the path for regulatory submission of Chronocort for adult CAH
in Europe before the end of 2019. It has also allowed DNL to revise the
primary endpoint in the protocol for the US Chronocort Phase III
trial.Please click on the link below for the full report:
https://www.hardmanandco.com/?post_type=research&p=3627&preview=true [1]
If you are interested in meeting the company, you can register your interest
by clicking on the above link
To contact us: Contact:
Hardman & Co Dr Martin Hall mh@hardmanandco.com
35 New Broad Street dmh@hardmanandco.com
London gp@hardmanandco.com
EC2M 1NH
Dr Dorothea
Hill
www.hardmanandco.com
Dr Gregoire
Pave
Follow us on Twitter
@HardmanandCo +44 20 7194
7622
Hardman & Co Research can still be accessed for free after MiFID II. Please
click here [2] to read the statement.
About Hardman & Co: For the past 21 years Hardman has been producing
specialist research designed to improve investors' understanding of
companies, sectors, industries and investment securities. Our analysts are
highly experienced in their sectors, and have often been highly rated by
professional investors for their knowledge. Our focus is to raise companies'
profiles across the UK and abroad with outstanding research, investor
engagement programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this is
clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed
representative of Capital Markets Strategy Ltd and is authorised and
regulated by the Financial Conduct Authority; our FCA registration number is
600843. Hardman Research Ltd is registered at Companies House with number
8256259.
Our research is provided for the use of the professional investment
community, market counterparties and sophisticated and high net worth
investors as defined in the rules of the regulatory bodies. It is not
intended to be made available to unsophisticated retail investors. Anyone
who is unsure of their categorisation should consult their professional
advisors. This research is neither an offer, nor a solicitation, to buy or
sell any security. Please read the note for the full disclaimer.
Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service
904181 05-Nov-2019
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=46998b5da59d8bbefebf2afde01c84e9&application_id=904181&site_id=vwd&application_name=news
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=5a632f52f80bd372265e4041a743aa1c&application_id=904181&site_id=vwd&application_name=news
(END) Dow Jones Newswires
November 05, 2019 02:30 ET (07:30 GMT)
